Head-to-head · WeighScore
Freya Meds vs PlexusDx
The verdict
PlexusDx takes it — 67.7/100 to 58.6/100.
PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Freya Meds | PlexusDx |
|---|---|---|
| WeighScore | 58.6/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #364 | #161 |
| Semaglutide | $297/mo (compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | $390/mo (compounded) | $249/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #364 · C
Strengths
- GLP-1 specialist — not a multi-category telehealth
- Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
- Both semaglutide and tirzepatide available
- Multi-month discount on quarterly billing
- Claims 450,000+ enrolled
Where it loses points
- No visible LegitScript or PCAB accreditation
- Above-average pricing ($250–$390/mo)
- Compounded only — no brand-name options
- Now serves 49 U.S. states (one state excluded; specific exclusion not named)
Graded #161 · C
Strengths
- Licensed providers available in all 50 states
- Range of options including low-cost microdose GLP-1 from $129/mo
- Optional Precision Peptide genetic panel adds a personalization angle
- Independent clinician review via state-licensed telehealth platform
- Compounded medications from state-licensed pharmacies
Where it loses points
- Compounded medications only; no FDA-approved brand options
- Specific compounding pharmacies not named
- Genetic-panel upsell may not add clinical value for everyone
- Tirzepatide pricing from $249/mo is higher than budget rivals
- No insurance accepted
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.